Combinatorial and Orthogonal Approaches to Improving Antitumor Immune Responses in H3K27-mutated DIPG/DMG
Personalized Radiotherapy for Pediatric Diffuse Midline Glioma
Correlatives of Disease Response in Patients Treated with Quad-Targeting CAR T Cell Therapy
A mRNA-Based Approach for Reprogramming Tumor-Associated Macrophages to Target and Hunt Diffuse Midline Glioma
Unraveling Single-Cell Epigenetic Dysregulation and Risk Variants in Diffuse Midline Glioma
Innovative MAPK-Targeting strategies for Young DIPG Fighters: Expanding Therapeutic Benefits
TREM2 Modulation as an Immunotherapeutic Strategy for DIPG
DMG PIONEER: Pioneering the Integration of Multiomics Data and Patient Therapy Response
An Innovative DIPG Therapy Using a Brain Penetrable Polymer-Modified NanoMedicine
Targeting Aberrant Long-range Polycomb Chromatin Looping in DIPG
Enhancing Therapeutic Delivery in Diffuse Intrinsic Pontine Glioma
Fellowship for CAR-T Study
Investing DIPG Tumor Dependencies on Branched Chain Amino Acid Catabolism through Therapeutic Dietary Restriction
Enhancing CAR-T Therapy through Immunomodulation of the Tumor Microenvironment by Blocking TIM-3
Targeting Adaptive Immune Niche in the Skull Bone Marrow for Novel Immunotherapy
Targeting Mechanisms of Treatment Resistance in Diffuse Midline Glioma
Lipid Dependent Mechanisms Underlying Cell State Specification in H3K27M Diffuse Midline Glioma
Elucidating the Mechanism of EGFR Mediated Resistance to ONC201 in H3K27M Mutant Diffuse Midline Glioma
Harnessing Oncolytic Adenoviruses for Targeted Diffuse Midline Glioma Therapy
Engineering Enhanced Gamma Delta T-Cells to Overcome DIPG Immune Resistance
Inhibition of Mitochondrial ROS Scavenging as a Novel Treatment for DMG
Targeting DNA Replication Stress to Induce Innate Inflammation in Diffuse Midline Gliomas with H3K27M Mutations
Targeting Energy Metabolism in Diffuse Intrinsic Pontine Glioma
Development of Novel Nanoelectronics-based Treatment for Diffuse Intrinsic Pontine Glioma: A Multifaceted Technology to Overcome Treatment Challenges
Attacking the Achilles’ Heel of Diffuse Midline Gliomas with Innovative H3K27M-Targeting Chemical Probes
Tracing the Origins of DIPG
Single Cell Epi-Multiomic Characterization of the Cellular Hierarchy in H3K27M Diffuse Midline Glioma to Leverage Intrinsic Tumor Cell Plasticity Towards Novel Therapeutic Targets
Immunometabolic Modulation of Diffuse Midline Glioma Response to Therapy
Multimodal Systems for Molecular Profiling and Therapeutic Tracking of DIPG
Investigation of the Efficacy of Combinatorial ONC206 and B7-H3 CAR T Cells Against DIPG/DMG Models
Targeting Voltage-Sensitive Mechanisms of DIPG Growth
Molecular Elucidation of DIPG Surface Signaling in Response to NLGN3
Identifying DIPG Vulnerabilities Conferred by Whole-Arm Chromosomal Alterations
Combining Virotherapy and Anti-GD2 CAR T Cells for Diffuse Midline Glioma
Therapeutic Targeting of H3K27M-Driven Folate Metabolism in DIPGs
Immunomodulation of the Tumor Microenvironment in DIPG by Oncolytic Virotherapy
Assessing the Potential of Givinostat, Paxalisib and Radiotherapy Combination Therapies for the Treatment of DIPG
Investigating the Roles of Lactate as Metabolic Fuel and Epigenetic Modifier in H3K27M DIPGs
Targeting Communication Networks in DIPG
Identifying and Targeting Developmental Vulnerabilities of Diffuse Midline Gliomas
Engineering Enhanced GD2 CAR T-Cells to Overcome DIPG Immune Resistance
Reprogramming the Tumor Microenvironment in DIPG with Engineered iPSC-NK Cells to Improve Immunotherapy
Immune Determinants of GD2 CAR T-Cell Activity in Patients with DIPG
Defining the Tumor Intrinsic and Regional Landscape of Therapeutic RNA-Nanoparticle Transduction and Immune Activation Following Intravenous Administration in DIPG
Targeting Aberrant RNA Translation in DIPG
In Vivo Imaging of Diffuse Midline Gliomas
C7R-GD2 CAR T-Cells for DMG: Clinical Trial of Dual Route Strategy
CLIA certified assays for plasma-based disease response monitoring in histone mutant gliomas
CD155 as a Novel Regulator of Cell Growth and Immune Evasion in DIPG
Advancing data analyses of DMG tumors
Deciphering Aberrant RNA Translation in DIPG
Exploring H3K27ac Deregulation as Therapeutically Actionable in Histone Mutant Pediatric DIPG
Remodeling Lipid Metabolism for Therapeutic Differentiation of H3K27M DIPG
Neurophysiological Small Molecule Screen for Inhibitors of Neuron-to-DIPG Communication
Targeting Combined Metabolic and Epigenetic Pathways H3K27M DIPG
Integrating Systemic and Local Therapeutic Vulnerabilities to Improve the Treatment of Diffuse Midline Glioma
Tumor-Targeted pan-RAS Inhibition as a Novel Therapy for Diffuse Intrinsic Pontine Glioma (DIPG)
Determining the Effect of ONC201 on DIPG Cellular Metabolism and Targeting Mechanisms of Resistance
Exploring copper chelation as a novel epigenetic therapeutic strategy for DIPG
Combinatorial targeting of Cyclin-Dependent Kinases in DIPG
Dissecting mechanisms of radio resistance associated with p53 mutations in DIPG
Targeting the electrical vulnerabilities of DIPG by modulating the neuronal microenvironment
A clinically translatable nanotherapeutic approach to enhance BBB drug delivery in DIPG
Targeting Diffuse Midline Gliomas with Rational Combination Therapy
Development of a Comprehensive Direct Drug Delivery Platform for the Treatment of Diffuse Midline Glioma
Targeted Protein Degradation of LSD1 as a Therapeutic Strategy in DIPG
Therapeutic targeting of the PBAF chromatin remodeling complex in diffuse intrinsic pontine gliomas
Supporting CAR T Trial: Neuro-Immuno-Oncology (NIO) fellowship program
Targeting T-cell intrinsic and extrinsic regulators to improve T cell therapies in DIPGs
Epigenetic regulation of phenotypic plasticity in DIPG
Use of H3(K27M) – Driven Zebrafish Models to Identify Targetable Vulnerabilities in DIPG
Epigenetically activated ID1 is a key transcriptional regulator of DIPG Invasion and is targetable with cannabidiol.
MYC activation in Diffuse Intrinsic Pontine Gliomas
MYC activation in Diffuse Intrinsic Pontine Gliomas
Oncolytic Immunotherapy for Diffuse Intrinsic Pontine Gliomas
Targeting DIPG using novel CAR-T cell therapy
Metabolic therapies for DIPGs
Viroimmunotherapeutic strategies to heat up DIPG microenvironment. A comprehensive approach to unleash anti-tumor immune response.
Targeting the electrophysiological response to GABA in DIPG through neurological and neuropsychiatric drug repurposing
DMG-ACT Trial
Enhancing the efficacy of radiation therapy for DIPG
Interrogating the role of POU Transcription Factor Driven ERV Activation in H3K27M Diffuse Midline Glioma
Unlocking oncogene addition to identify synergistic treatment targets for the treatment of DIPG
ONC201 in DIPG; establishing mechanism, enhancing efficacy and determining long-term phenotypic consequences
Dependence of DIPGs on DNA polymerase for DNA repair defines a new therapeutic target.
Next-generation CAR T cell therapies for treatment of DIPG, utilizing sequential ‘prime-and-kill’ circuits to achieve safe and effective tumor targeting
Dissecting mechanisms of H3K27M oncohistone function in DIPG
Mechanistic studies on the WNT5A signal pathway in DIPG tumor
Targeting epigenetically induced vulnerabilities in DIPG
Targeting DIPGs by interrupting metabolic pathways
Characterizing long non-coding RNAs as therapeutic targets in diffuse intrinsic pontine glioma
Optimal combinatorial targeting of HDAC inhibition and radiation in DIPG
MIC2 inhibition mediated apoptosis in DIPG
Therapeutic Targeting of Metabolic Vulnerabilities in DIPG
Use of a Long Non-coding RNA (lncRNA) as a Therapeutic Target in DIPG.
Targeting metabolic regulation of the epigenome in DIPG
Targeting Cancer Stem Cells in DIPG.
Therapeutic targetiing of the disrupted metabolic state in DIPG to induce ferroptotic cell death.
Mass Spectroscopy Instrument
Expanded Access Program for ONC201